Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral direct-acting antiviral therapies for serious viral diseases. The company’s pipeline centers on two primary programs: a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection, and AT-587 for the treatment of chronic hepatitis E virus (HEV) infection in immunocompromised patients. Bemnifosbuvir is a nucleotide analog polymerase inhibitor, while ruzasvir is an NS5A inhibitor; the combination is being evaluated in global Phase 3 clinical trials, including C-BEYOND and C-FORWARD, to improve upon current standard of care. AT-587 is a novel double prodrug nucleotide analog designed to address the unmet medical need for direct-acting antivirals in HEV. The company leverages a proprietary platform of nucleosides and nucleotides to develop candidates targeting single-stranded ribonucleic acid (ssRNA) viruses. Atea has established a strategic collaboration with Roche to develop and commercialize AT-527 for patients with COVID-19. The company’s operations span medicinal chemistry, virology, and clinical development, with a focus on creating differentiated, orally administered antivirals.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ateapharma.com
Sector Healthcare IR page ir.ateapharma.com
Tags
antiviral therapies, hepatitis c, hepatitis e, nucleoside analogs, direct-acting antivirals, clinical-stage, ssrna viruses, medicinal chemistry, virology, oral therapeutics, bemnifosbuvir, ruzasvir, AT-587, AT-527, C-BEYOND, C-FORWARD, Epclusa, Mavyret, sofosbuvir, velpatasvir
Press page —

Metrics

Valuation  
Market cap $ 317.182M
Market cap (USD) $ 317.182M
P/E -2.03
PEG —
P/BV 1.81
P/S 0.90
P/OCF -2.26
P/FCF -2.40
Dividend yield —
Turnover / mcap —
Returns  
ROE -44.3%
ROI -88.1%
ROIC -75.5%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 46
Quality score -35.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue — — — — 351.367M 48.633M — 7.8M
Net profit -158.349M -168.385M -135.956M -115.909M 121.19M -10.947M -14.034M -24.735M
Free cash flow -132.031M -135.499M -85.395M -122.925M -87.009M 296.708M -12.831M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 3.57 3.35 3.05 4.81 8.94 41.78 — 0.82
Price performance 12m 0.07 0.1 -0.37 -0.46 -0.79 — — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — — 197,000 3.12M 2.4M 1.64M 843,000
Cash and deposits (USD) 15M 34.6M 21.7M 850M 764M 188M 144M 64.7M 95.7M
Right-of-use assets (USD) — — — — 161,000 2.39M 1.83M 1.24M 634,000
Cash flow detail
Operating cash flow (USD) — -7.91M -12.8M 297M -87M -121M -85.4M -135M -132M
Purchases of property, plant and equipment (USD) — -12,000 -2,000 -26,000 -4,000 -1.94M — — —
Change in receivables (cash effect) (USD) — — — -5.82M — — — — —
Change in payables (cash effect) (USD) — -90,000 157,000 -488,000 10.3M -1.98M 1.7M 206,000 8.49M
Share buybacks (cash effect) (USD) — — — — — — — 0.00 -25.5M
Share-based compensation (USD) — 414,000 624,000 7.46M 39.6M 46.7M 49.4M 51.8M 20.7M
Operating cash flow before change in receivables (USD) — — — 303M — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) — -7.92M -12.8M 297M -87M -123M — — —
Income detail
Research and development expense (USD) — 6.68M 10.2M 38M 167M 81.9M 114M 144M 148M
↳ 5y CAGR +76.5% +69.9% +31.2%
Total comprehensive income (USD) — 0.00 0.00 0.00 0.00 -117M -135M -168M -158M
Comprehensive income to owners (USD) — 0.00 0.00 0.00 0.00 -117M -135M -168M -158M
Reported Mar 30, 2021 Mar 30, 2021 Mar 30, 2021 Mar 30, 2021 Feb 28, 2022 Feb 28, 2023 Feb 28, 2024 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection

Phase 3 C-FORWARD Trial for HCV on Track for Topline Results in Early 2027

Phase 1 Trial Evaluating AT-587 as Potential First-in-Class Treatment for Chronic Hepatitis E Virus (HEV) Infection Advances

Secured Non-dilutive Funding from Hercules Capital in an Amount Up to $200 Million

Company Holding Conference Call Today at 4:30 pm ET

BOSTON, Mass., November 9, 2026 – Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

On November 6, 2026 (the “Closing Date”), Atea Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Hercules Capital, Inc. (“Hercules”), as agent, and the lenders party thereto, providing for term loans in an aggregate principal amount of up to $200.0 million, subject to the terms and conditions set forth therein. The Agreement provides for senior secured term loans which mature on November 1, 2031 (the “Maturity Date”), for up to $200.0 million and consists of the following tranches (collectively, the “Term Loans”): (1) a Tranche 1 Term Loan of $65.0 million drawn on the Closing Date, (2) a Tranche 2 Term Loan of up to $35.0 million, (3) a Tranche 3 Term Loan up to the difference between $35.0 million and the amounts funded under Tranche 4, (4) a Tranche 4 Term Loan up to the difference between $70.0 million and the amounts funded under Tranche 3, and (5) a Tranche 5 Term Loan of up to $30.0 million.

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2026, and to provide a business update.

To access the live conference call, participants may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.

About Atea Pharmaceuticals

Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat ssRNA viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s Phase 3 program is evaluating the fixed dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment hepatitis C virus (HCV). AT-587, a nucleotide analog, is in Phase 1 development for the treatment of hepatitis E virus (HEV). For more information, please visit www.ateapharma.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company’s plans relating to the date and time of the anticipated conference call and audio webcast. When used herein, words including “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. Forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Prompts

Atea Pharmaceuticals, Inc. (ticker AVIR), listed in United States.

ETFs Holding Atea Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.02% 150,601 $ 620.476K Nov 16, 2026
FESM 0.01% 94,351 $ 438.732K Jun 30, 2026
DFAS 0.01% 597,421 $ 2.515M Nov 12, 2026
DCOR 0.00% 89,600 $ 377.216K Nov 12, 2026
DFAU 0.00% 16,361 $ 68.88K Nov 12, 2026
DXUV 0.00% 7,834 $ 32.981K Nov 12, 2026
DFAC 0.00% 74,958 $ 315.573K Nov 12, 2026
DFUS 0.00% 9,202 $ 38.74K Nov 12, 2026
AVUS 0.00% 11,053 $ 45.538K Nov 16, 2026